<div id="readability-page-1"><article>SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the first quarter of 2026 by conference call on Friday, May 15, 2026 at 4:30 PM EDT. Following management’s formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to: https://dpregister.com/sreg/10209272/104069d5d88. Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=Rt7kKGAp. A webcast replay of the call will be available approximately one hour after the end of the call through approximately August 15, 2026 at the following link: https://services.choruscall.com/ccforms/replay.html. A telephonic replay of the call will also be available and may be accessed by calling 1-855-669-9658 (toll free domestic/Canada), 1-412-317-0088 (international toll) by using access code 4737992. About BioCardia® BioCardia, Inc., headquartered in Sunnyvale, California, is a developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms for the treatment of heart disease. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms. BioCardia also acts as a biotherapeutic delivery partner supporting therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction. For more information visit www.biocardia.com. <img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE56ZzBOaU0zTlRrMk9EYzBJekl3TVRrNE1Uaz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE56ZzBOaU0zTlRrMk9EYzBJekl3TVRrNE1Uaz0"/> <img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZDRkYTIxYWItNjZkYS00NzRhLThlZDYtYWM0Zjg5NTMyMTk3LTEwMzEzOTEtMjAyNi0wNS0xMS1lbg==/tiny/BioCardia-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZDRkYTIxYWItNjZkYS00NzRhLThlZDYtYWM0Zjg5NTMyMTk3LTEwMzEzOTEtMjAyNi0wNS0xMS1lbg==/tiny/BioCardia-Inc-.png"/> <pre>MEDIA CONTACT:Miranda Peto, Investor Relationsmpeto@biocardia.com(650) 226-0120INVESTOR CONTACT:David McClung, Chief Financial Officerinvestors@biocardia.com(650) 226-0120</pre></article></div>

BCDA

IBBQ

SBIO

LABU

BioCardia, Inc. will host a conference call on May 15, 2026, at 4:30 PM EDT to discuss its Q1 2026 financial results and provide a corporate update. The call will include a Q&A session following management's remarks. Participants can register for the call and will receive dial-in information upon registration. The call will also be available via live webcast, with a replay accessible for a limited time afterward. BioCardia specializes in cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases.

StockTitan

BioCardia

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

ALPS Medical Breakthrough

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026 | BCDA Stock News